Related Experiment Video

Updated: Jul 19, 2026

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors

Published on: July 17, 2020

A novel proteasome inhibitor NPI-0052 as an anticancer therapy

D Chauhan1, T Hideshima, K C Anderson

  • 1Department of Medical Oncology, Harvard Medical School, Dana Farber Cancer Institute, The Jerome Lipper Multiple Myeloma Center, Boston, MA 02115, USA.

British Journal of Cancer
|October 19, 2006
PubMed

Insights

A new proteasome inhibitor, NPI-0052, shows promise for treating multiple myeloma (MM) by overcoming drug resistance and showing good tolerability in preclinical studies. This offers a potential new therapy for patients with relapsed or refractory MM.

Area of Science:

  • Oncology
  • Pharmacology
  • Biochemistry

Background:

  • Bortezomib (Velcade) is an effective proteasome inhibitor for multiple myeloma (MM).
  • Prolonged Bortezomib treatment can lead to toxicity and drug resistance.
  • There is a need for novel therapeutic agents to overcome Bortezomib resistance in MM.

Purpose of the Study:

  • To review the novel proteasome inhibitor NPI-0052.
  • To compare NPI-0052 with Bortezomib in terms of chemical structure, mechanism of action, and efficacy.
  • To highlight NPI-0052's potential to overcome resistance to conventional therapies.

Main Methods:

  • Review of preclinical data on NPI-0052.
  • In vivo studies using human multiple myeloma xenografts.
  • Assessment of NPI-0052's tolerability, survival effects, and tumor recurrence reduction.

Main Results:

  • NPI-0052 possesses a distinct chemical structure and mechanism of action compared to Bortezomib.
  • NPI-0052 effectively overcomes resistance to conventional and Bortezomib therapies.
  • In vivo studies demonstrated that NPI-0052 is well tolerated, prolongs survival, and reduces tumor recurrence in MM xenografts.

Conclusions:

  • NPI-0052 represents a promising novel proteasome inhibitor for multiple myeloma.
  • Preclinical data support the advancement of NPI-0052 into clinical trials for relapsed/refractory MM.
  • NPI-0052 has the potential to address unmet needs in MM treatment, particularly in resistant cases.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...